Search the database for deliberate release of GM medicinal products
| EU record number |
Title |
Company / Sponsor |
Treated organism |
Genetic modification |
| Only notified under the "contained use" procedure. Dossier submitted on
. |
A Phase 2, randomized, open-label, controlled study to evaluate the efficacy and safety of rapcabtagene autoleucel versus comparator in participants with severe refractory idiopathic inflammatory myopathies. |
Novartis Pharma Services AG |
Humans |
CD19 CAR |
| Only notified under the "contained use" procedure. Dossier submitted on
. |
Phase II study evaluating rapcabtagene autoleucel in participants with diffuse cutaneous systemic sclerosis (dcSSc) |
Novartis Pharma Services AG |
Humans |
CD19 CAR |
| Only notified under the "contained use" procedure. Dossier submitted on
. |
A phase II, single-arm, multi-center trial to determine the efficacy and safety of CTL019 in pediatric patients with relapsed and refractory B-cell acute lymphoblastic leukemia |
Novartis Pharma Services AG |
Humans |
Chimeric antigen receptor against CD19 |
| Only notified under the "contained use" procedure. Dossier submitted on
. |
A multicenter, randomized, double-blind, placebo-controlled study evaluating the efficacy of Biobypass (ADGVVEGF121.10NH) delivered by NOGATM-guided/MYOSTARTM catheter in "no option" patients with class II-IV stable angina |
GenVec, Inc. |
Humans |
human VEGF121 |
| B/BE/04/BV1 |
Evaluation of the safety of Feline Herpes Virus, bivalent deleted live vaccine, administered as intranasal vaccine to cats |
Pfizer, Animal Health Group |
cats |
gene for the env glycoprotein or gene for the gag protein of the Feline immunodeficiency virus (FIV) |
